These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32339530)

  • 21. A predicted immunity protein confers resistance to pyocin S5 in a sensitive strain of Pseudomonas aeruginosa.
    Rasouliha BH; Ling H; Ho CL; Chang MW
    Chembiochem; 2013 Dec; 14(18):2444-6. PubMed ID: 24222552
    [No Abstract]   [Full Text] [Related]  

  • 22. Plant-expressed pyocins for control of Pseudomonas aeruginosa.
    Paškevičius Š; Starkevič U; Misiūnas A; Vitkauskienė A; Gleba Y; Ražanskienė A
    PLoS One; 2017; 12(10):e0185782. PubMed ID: 28973027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriocin-mediated competition in cystic fibrosis lung infections.
    Ghoul M; West SA; Johansen HK; Molin S; Harrison OB; Maiden MC; Jelsbak L; Bruce JB; Griffin AS
    Proc Biol Sci; 2015 Sep; 282(1814):. PubMed ID: 26311664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA Damage-Inducible Pyocin Expression Is Independent of RecA in
    Bronson AS; Baggett NS; Cabeen MT
    Microbiol Spectr; 2022 Aug; 10(4):e0116722. PubMed ID: 35708338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of iron concentration in the growth medium on the sensitivity of Pseudomonas aeruginosa to pyocin S2.
    Ohkawa I; Shiga S; Kageyama M
    J Biochem; 1980 Jan; 87(1):323-31. PubMed ID: 6766926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relations between antibiotic resistance and pyocin P3 resistance in Pseudomonas aeruginosa mutants].
    García-Quintana HG; Wilckens R
    Zentralbl Veterinarmed B; 1983 Apr; 30(3):169-74. PubMed ID: 6408850
    [No Abstract]   [Full Text] [Related]  

  • 27. Pore-forming pyocin S5 utilizes the FptA ferripyochelin receptor to kill Pseudomonas aeruginosa.
    Elfarash A; Dingemans J; Ye L; Hassan AA; Craggs M; Reimmann C; Thomas MS; Cornelis P
    Microbiology (Reading); 2014 Feb; 160(Pt 2):261-269. PubMed ID: 24217175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and characterization of pyocin-colicin chimeric proteins.
    Kageyama M; Kobayashi M; Sano Y; Masaki H
    J Bacteriol; 1996 Jan; 178(1):103-10. PubMed ID: 8550402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploitation of an iron transporter for bacterial protein antibiotic import.
    White P; Joshi A; Rassam P; Housden NG; Kaminska R; Goult JD; Redfield C; McCaughey LC; Walker D; Mohammed S; Kleanthous C
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12051-12056. PubMed ID: 29078392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis.
    Six A; Mosbahi K; Barge M; Kleanthous C; Evans T; Walker D
    J Antimicrob Chemother; 2021 Aug; 76(9):2317-2324. PubMed ID: 34142136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients.
    Redero M; López-Causapé C; Aznar J; Oliver A; Blázquez J; Prieto AI
    J Antimicrob Chemother; 2018 Oct; 73(10):2770-2776. PubMed ID: 30052973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical properties of a new flexuous bacteriocin, pyocin F1, produced by Pseudomonas aeruginosa.
    Kuroda K; Kageyama M
    J Biochem; 1979 Jan; 85(1):7-19. PubMed ID: 104991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model.
    Scholl D; Martin DW
    Antimicrob Agents Chemother; 2008 May; 52(5):1647-52. PubMed ID: 18332164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibiotic sensitivity and pyocin dependence of clinical strains of Ps. aeruginosa].
    Savitskaia KI; Levina EN
    Antibiotiki; 1977 Dec; 22(12):1117-21. PubMed ID: 413475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pyocin typing of Pseudomonas aeruginosa strains].
    Moroz AF; Petropavlovskaia IS; Osokina TI; Frolova VV
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):31-5. PubMed ID: 6422681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of antibiotic resistance phenotype to the R-pyocin susceptibility pattern in clinical isolates of Pseudomonas aeruginosa.
    Tzouvelekis LS; Tumah H; Malliara K; Legakis NJ
    J Chemother; 1989 Aug; 1(4):226-30. PubMed ID: 2509643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of lipopolysaccharide mutants and R2-Pyocin susceptible variants in
    Mei M; Pheng P; Kurzeja-Edwards D; Diggle SP
    bioRxiv; 2023 Sep; ():. PubMed ID: 37163048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Neisseria gonorrhoeae by a bacteriocin from Pseudomonas aeruginosa.
    Morse SA; Vaughan P; Johnson D; Iglewski BH
    Antimicrob Agents Chemother; 1976 Aug; 10(2):354-62. PubMed ID: 825024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retargeting R-type pyocins to generate novel bactericidal protein complexes.
    Williams SR; Gebhart D; Martin DW; Scholl D
    Appl Environ Microbiol; 2008 Jun; 74(12):3868-76. PubMed ID: 18441117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study on R-type pyocins of Pseudomonas aeruginosa.
    Ohsumi M; Shinomiya T; Kageyama M
    J Biochem; 1980 Apr; 87(4):1119-25. PubMed ID: 6771248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.